Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159768 | 1.00 | NAMPT (0.77) | NAMPTCYP2C9 | |
| SCHEMBL160563 | 0.93 | NAMPT (0.77) | NAMPTCYP2C9 | |
| SCHEMBL162094 | 0.92 | NAMPT (0.91) | NAMPTCYP2C9 | |
| SCHEMBL12467946 | 0.91 | NAMPT (0.77) | NAMPTCYP2C9 | |
| SCHEMBL173345 | 0.88 | NAMPT (0.69) | NAMPTCYP2C9 | |
| SCHEMBL163570 | 0.88 | NAMPT (0.69) | NAMPTCYP2C9 | |
| SCHEMBL12468291 | 0.88 | NAMPT (0.79) | NAMPTCYP2C9 | |
| SCHEMBL16107990 | 0.88 | NAMPT (0.68) | NAMPTCYP2C9 | |
| SCHEMBL12468215 | 0.88 | NAMPT (0.68) | NAMPTCYP2C9 | |
| SCHEMBL174192 | 0.88 | NAMPT (0.68) | NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | NAMPT 1/4885CYP2C9 772/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP2C9 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.